In this survey of primary care providers in the ATHS, we found general agreement about the frequency of post-treatment PSA monitoring (i.e. every 12 months) and the preferred individual in charge of life-long prostate cancer surveillance (i.e. primary care provider) for a hypothetical prostate cancer survivor described in a clinical scenario. The gene discussed is KLK3; the disease is prostate cancer.